Q-omics provides the consensus-scored LENG8 profile across patient tissues and cancer cell-line models. LENG8 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, LENG8 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, LENG8 RNA expression shows 20,123 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight BLCA, KIRC, and UVM as cancer lineages where LENG8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LENG8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LENG8 survival associations across molecular data types. LENG8 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (10) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LENG8 RNA expression–survival associations across cancer types. High LENG8 expression shows unfavorable associations in KIRC, CESC, ACC, COAD and LGG, but favorable associations in BLCA. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for LENG8 RNA expression.
This table summarizes LENG8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for LENG8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LENG8 shows lower tumor expression in BRCA and higher tumor expression in KIRC, COAD, HNSC, LIHC and CHOL. The KIRC box plot shows higher LENG8 RNA expression in tumor versus normal tissue (log2 FC = +0.718, t-test p < 0.001).
This table shows molecular features associated with LENG8 in patient tissues and cancer cell lines. In patient samples, LENG8 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, LENG8 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in CNS and SOFT_TISSUE.
